A link between the increased levels of A1AR observed under the same conditions and ADA activity may be one hypothesis, while the interaction between ADA and CD26 may be another: this cell surface peptidase is involved in glucose and insulin regulation mechanisms, and selective CD26 inhibitors are being studied as a safe therapy for diabetes type 2 [50], [51]. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.